Fulcrum Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Fulcrum Therapeutics, Inc. – FULC

Fulcrum Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Fulcrum Therapeutics, Inc. – FULC

NEW ORLEANS–(BUSINESS WIRE)–
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Fulcrum Therapeutics, Inc. (NasdaqGM: FULC) and Slate Medicines, Inc. Upon closing of the proposed transaction, Fulcrum shareholders are expected to own 5.0% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to Fulcrum shareholders.

If you would like to discuss your legal rights regarding the proposed transaction, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ([email protected]) toll free at any time at (833) 538-3612, or visit https://www.ksfcounsel.com/cases/nasdaqgm-fulc/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

Kahn Swick & Foti, LLC

Lewis Kahn, Managing Partner

[email protected]

1-833-538-3606

1100 Poydras St., Suite 960

New Orleans, LA 70163

KEYWORDS: Louisiana United States North America

INDUSTRY KEYWORDS: Professional Services Class Action Lawsuit

MEDIA:

Logo
Logo